AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24533491 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dynamic stretching)
Number of subjects: 37
Study 22497967 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastroretentive gabapentin (G-GR) 3000mg once daily (G-GR-QD)
Number of subjects: 147
Study 22497967 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastroretentive gabapentin (G-GR) divided dose (G-GR-DD, 1200mg AM/1800mg PM)
Number of subjects: 147
Study 22497967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 147
Study 20941926 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20941926 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 0
Study 18539989 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 5 or 2.5 mg
Number of subjects: 8
Study 18539989 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 16105600 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced surface ablation
Number of subjects: 28
Study 12917299 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity warfarin therapy (target INR of 1.5 to 1.9)
Number of subjects: 738
Study 12917299 — intervention group
Group type: COMPARATOR
Intervention: Conventional-intensity warfarin therapy (target INR of 2.0 to 3.0)
Number of subjects: 738
Study 10622270 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise
Number of subjects: 20
Study 10622270 — intervention group
Group type: COMPARATOR
Intervention: Iloprost treatment (0.5-2 ng/Kg/min)
Number of subjects: 20
Study 8556228 — intervention group
Group type: COMPARATOR
Intervention: UFT therapy alone
Number of subjects: 45
Study 8556228 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT therapy in combination with Bestatin
Number of subjects: 45
Study 1951565 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic amnioinfusion
Number of subjects: 305
Study 1951565 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 305
Study 7034155 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine, 1 g/day
Number of subjects: 72
Study 7034155 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacid/anticholinergic (10 ml of antacid suspension and 0.6 mg L-hyoscyamine twice a day)
Number of subjects: 72
Study 7034155 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 7034155 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacid/anticholinergic
Number of subjects: 72
Study 31729566 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month exercise program of supervised indoor and outdoor group sessions in addition to usual nutritional care (n = 41)
Number of subjects: 60
Study 31729566 — intervention group
Group type: COMPARATOR
Intervention: Usual nutritional care group receiving dietary and physical activity counseling (n = 19)
Number of subjects: 60
Study 29074061 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (first-line)
Number of subjects: 245
Study 29074061 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (first- or second-line)
Number of subjects: 245
Study 29074061 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Number of subjects: 245
Study 29074061 — intervention group
Group type: EXPERIMENTAL
Intervention: Abiraterone or Enzalutamide
Number of subjects: 245
Study 26716863 — intervention group
Group type: EXPERIMENTAL
Intervention: NAVA with sevoflurane
Number of subjects: 9
Study 26716863 — intervention group
Group type: EXPERIMENTAL
Intervention: NAVA with propofol
Number of subjects: 9
Study 26716863 — intervention group
Group type: EXPERIMENTAL
Intervention: NAVA with sevoflurane and remifentanil
Number of subjects: 9
Study 26716863 — intervention group
Group type: EXPERIMENTAL
Intervention: NAVA with propofol and remifentanil
Number of subjects: 9
Study 24690159 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole grain and legume group (n=92)
Number of subjects: 185
Study 24690159 — intervention group
Group type: COMPARATOR
Intervention: Refined rice group (n=93)
Number of subjects: 185
Study 22278643 — intervention group
Group type: EXPERIMENTAL
Intervention: Healing Touch (HT)
Number of subjects: 41
Study 22278643 — intervention group
Group type: COMPARATOR
Intervention: Standard Treatment (ST)
Number of subjects: 41
Study 20372083 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal influenza vaccination
Number of subjects: 5305
Study 20372083 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular vaccination
Number of subjects: 5305
Study 20372083 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal microinjection system
Number of subjects: 5305
Study 20372083 — intervention group
Group type: COMPARATOR
Intervention: Conventional intramuscular syringe
Number of subjects: 5305
Study 18620598 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard of care and Procalcitonin guided diagnostics and treatment of infection
Number of subjects: 1000
Study 18620598 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 1000
Study 16093865 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a (40 kDa) plus ribavirin for 48 weeks
Number of subjects: 0
Study 16093865 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a (40 kDa) plus ribavirin for 72 weeks
Number of subjects: 0
Study 16093865 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose induction regimen with peginterferon alfa-2a (40 kDa) 360 mug once-weekly for 12 weeks followed by 60 weeks of peginterferon alfa-2a (40 kDa) 180 mug once weekly
Number of subjects: 0
Study 16093865 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose induction regimen with peginterferon alfa-2a (40 kDa) 360 mug once-weekly for 12 weeks followed by 36 weeks of peginterferon alfa-2a (40 kDa) 180 mug once weekly
Number of subjects: 0
Study 16093865 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a (40 kDa) plus ribavirin
Number of subjects: 0
Study 12520671 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventricular Rate Stabilization (VRS) On
Number of subjects: 309
Study 12520671 — intervention group
Group type: COMPARATOR
Intervention: Ventricular Rate Stabilization (VRS) Off
Number of subjects: 309
Study 12520671 — intervention group
Group type: EXPERIMENTAL
Intervention: VRS On
Number of subjects: 309
Study 12520671 — intervention group
Group type: COMPARATOR
Intervention: VRS Off
Number of subjects: 309
Study 11042832 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-hr or 3-hr sperm-oocyte incubation
Number of subjects: 23
Study 11042832 — intervention group
Group type: COMPARATOR
Intervention: Standard overnight gamete co-incubation
Number of subjects: 23
Study 9104690 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright morning light (> 2,500 lux)
Number of subjects: 32
Study 9104690 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright evening light (PM; 19:00 to 21:00 h)
Number of subjects: 32
Study 9104690 — intervention group
Group type: COMPARATOR
Intervention: Dim red evening light (RED; < 10 lux)
Number of subjects: 32
Study 9104690 — intervention group
Group type: COMPARATOR
Intervention: Light therapy in NC subjects
Number of subjects: 32
Study 9104690 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of AM, PM, and RED light
Number of subjects: 32
Study 1343921 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxamniquine, single dosage of 15 mg/kg for adults and 20 mg/kg for children divided in two doses
Number of subjects: 0
Study 1343921 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel, single dose of 60 mg/kg
Number of subjects: 0
Study 1343921 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel, sequential doses of 60 mg/kg during 3 days or 30 mg/kg for 6 days
Number of subjects: 0
Study 1343921 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs (Oxamniquine and Praziquantel)
Number of subjects: 0
Study 3547254 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoromethalone 0.1% suspension (FML)
Number of subjects: 50
Study 3547254 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobetasone butyrate 0.1% (Eumovate)
Number of subjects: 50
Study 3547254 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone phosphate 0.1% (Betnesol)
Number of subjects: 50
Study 3547254 — intervention group
Group type: COMPARATOR
Intervention: Higher penetration steroids
Number of subjects: 50
Study 29409260 — intervention group
Group type: EXPERIMENTAL
Intervention: MTH preserving technique
Number of subjects: 23
Study 29409260 — intervention group
Group type: COMPARATOR
Intervention: MTH resecting technique
Number of subjects: 23
Study 28717985 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer teaching (PT)
Number of subjects: 79
Study 28717985 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer teaching using Peyton's four-step approach (PPT)
Number of subjects: 79
Study 28717985 — intervention group
Group type: EXPERIMENTAL
Intervention: Team based learning (TBL)
Number of subjects: 79
Study 28717985 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-based learning (VBL)
Number of subjects: 79
Study 26920441 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitting with 3 min bouts of light-intensity walking every 30 min
Number of subjects: 19
Study 26920441 — intervention group
Group type: COMPARATOR
Intervention: Uninterrupted sitting (sedentary condition)
Number of subjects: 19
Study 25589677 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Number of subjects: 1050
Study 25589677 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 1050
Study 23099447 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine monotherapy
Number of subjects: 0
Study 23099447 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium monotherapy
Number of subjects: 0
Study 21180354 — intervention group
Group type: EXPERIMENTAL
Intervention: Male and female perfumes as nonconscious stimulation during visual assessments
Number of subjects: 0
Study 18377975 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel (60 mg loading dose, 10 mg daily maintenance)
Number of subjects: 12844
Study 18377975 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (300 mg loading dose, 75 mg daily maintenance)
Number of subjects: 12844
Study 16775579 — intervention group
Group type: EXPERIMENTAL
Intervention: High soy diet (two daily soy servings)
Number of subjects: 24
Study 16775579 — intervention group
Group type: COMPARATOR
Intervention: Low soy diet (maintaining usual diet)
Number of subjects: 24
Study 14718746 — intervention group
Group type: EXPERIMENTAL
Intervention: Margarine containing medium-chain triacylglycerols (MCT)
Number of subjects: 73
Study 14718746 — intervention group
Group type: COMPARATOR
Intervention: Long-chain triacylglycerols (LCT)
Number of subjects: 73
Study 10976612 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretest assessment with interactive interventions (skills or demonstration)
Number of subjects: 0
Study 10976612 — intervention group
Group type: COMPARATOR
Intervention: No pretest assessment with interactive interventions (skills or demonstration)
Number of subjects: 0
Study 10976612 — intervention group
Group type: COMPARATOR
Intervention: Pamphlet review only (no pretest)
Number of subjects: 0
Study 10976612 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretest assessment
Number of subjects: 0
Study 10976612 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive interventions (skills or demonstration)
Number of subjects: 0
Study 10976612 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive intervention
Number of subjects: 0
Study 17429240 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiberoptic phototherapy (n=16)
Number of subjects: 46
Study 17429240 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional daylight phototherapy (n=15)
Number of subjects: 46
Study 17429240 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination phototherapy (n=15)
Number of subjects: 46
Study 1415973 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 24
Study 1415973 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 24
Study 31734218 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio-visual practice group (N = 177)
Number of subjects: 641
Study 31734218 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio-visual group (N = 157)
Number of subjects: 641
Study 31734218 — intervention group
Group type: COMPARATOR
Intervention: Control group (N = 114)
Number of subjects: 641
Study 31004470 — intervention group
Group type: EXPERIMENTAL
Intervention: Clazosentan (15 mg/hour for 3 hours) after rifampin (600 mg/100 mL in 30 minutes)
Number of subjects: 14
Study 31004470 — intervention group
Group type: COMPARATOR
Intervention: Clazosentan (15 mg/hour for 3 hours) after placebo
Number of subjects: 14
Study 28872919 — intervention group
Group type: EXPERIMENTAL
Intervention: Edaravone
Number of subjects: 368
Study 28872919 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 368
Study 25972279 — intervention group
Group type: EXPERIMENTAL
Intervention: ECO intervention (blended eHealth module embedded in Collaborative Occupational health care)
Number of subjects: 220
Study 25972279 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 220
Study 25972279 — intervention group
Group type: EXPERIMENTAL
Intervention: ECO intervention
Number of subjects: 220
Study 24308025 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low-intensity transcranial magnetic stimulation (8 Hz pulsed magnetic fields)
Number of subjects: 54
Study 24308025 — intervention group
Group type: COMPARATOR
Intervention: Sham group (no stimulation)
Number of subjects: 54
Study 21169619 — intervention group
Group type: EXPERIMENTAL
Intervention: Revised version of the website
Number of subjects: 77
Study 21169619 — intervention group
Group type: COMPARATOR
Intervention: Original version of the website
Number of subjects: 77
Study 19816871 — intervention group
Group type: EXPERIMENTAL
Intervention: High bolus dose tirofiban (25 microg/kg)
Number of subjects: 100
Study 19816871 — intervention group
Group type: COMPARATOR
Intervention: Control (saline bolus and infusion)
Number of subjects: 100
Study 19816871 — intervention group
Group type: EXPERIMENTAL
Intervention: High bolus dose tirofiban (25 microg/kg) in patients with diabetes mellitus
Number of subjects: 100
Study 17234504 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA-enriched nutrient mixture
Number of subjects: 48
Study 17234504 — intervention group
Group type: COMPARATOR
Intervention: Ordinary food (rice ball or bread)
Number of subjects: 48
Study 15133532 — intervention group
Group type: EXPERIMENTAL
Intervention: RPR749 (200 mg)
Number of subjects: 48
Study 15133532 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 12455284 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor rehabilitation
Number of subjects: 8
Study 9845975 — intervention group
Group type: EXPERIMENTAL
Intervention: Modeling
Number of subjects: 0
Study 9845975 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 9845975 — intervention group
Group type: EXPERIMENTAL
Intervention: Modeling with retrieval cues
Number of subjects: 0
Study 7814131 — intervention group
Group type: EXPERIMENTAL
Intervention: Injected thermoplasticized gutta‐percha
Number of subjects: 30
Study 7814131 — intervention group
Group type: COMPARATOR
Intervention: Lateral condensation technique
Number of subjects: 30
Study 2680677 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg/day piretanide
Number of subjects: 76
Study 2680677 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg/day piretanide
Number of subjects: 76
Study 2680677 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg/day bendroflumethiazide
Number of subjects: 76
Study 1127136 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen (500 mg/day)
Number of subjects: 18
Study 1127136 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 18
Study 31056442 — intervention group
Group type: EXPERIMENTAL
Intervention: VR‐THA simulation
Number of subjects: 14
Study 31056442 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 14
Study 28757438 — intervention group
Group type: EXPERIMENTAL
Intervention: Fascial Closure Device (FCD)
Number of subjects: 67
Study 28757438 — intervention group
Group type: COMPARATOR
Intervention: Traditional Fascial Closure (TFC)
Number of subjects: 67
Study 25647122 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based mastery learning session
Number of subjects: 42
Study 24947791 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal insulin peglispro (BIL) at doses ranging from 5.1 to 74.1 mU/min
Number of subjects: 8
Study 24947791 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine at doses of 20 or 30 mU/m(2)/min
Number of subjects: 8
Study 22259793 — intervention group
Group type: EXPERIMENTAL
Intervention: Panavia F 2.0
Number of subjects: 32
Study 22259793 — intervention group
Group type: EXPERIMENTAL
Intervention: Rely X Unicem
Number of subjects: 32
Study 22259793 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermocycled specimens
Number of subjects: 32
Study 22259793 — intervention group
Group type: COMPARATOR
Intervention: Natural teeth (control group)
Number of subjects: 32
Study 19321988 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention group A (oral health instructions + extra reminders)
Number of subjects: 242
Study 19321988 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention group B (oral health instructions)
Number of subjects: 242
Study 19321988 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 242
Study 17705104 — intervention group
Group type: EXPERIMENTAL
Intervention: INF-RIBA-AMA
Number of subjects: 30
Study 17705104 — intervention group
Group type: COMPARATOR
Intervention: INF-RIBA
Number of subjects: 30
Study 15377966 — intervention group
Group type: EXPERIMENTAL
Intervention: ACL-reconstructed group
Number of subjects: 46
Study 15377966 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 46
Study 11569479 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (Recormon), 20 IE/kg subcutaneously three times/week for 4 weeks
Number of subjects: 13
Study 11569479 — intervention group
Group type: COMPARATOR
Intervention: Control group (no erythropoietin treatment)
Number of subjects: 13
Study 9631134 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea (500 mg twice daily)
Number of subjects: 144
Study 9631134 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 7889226 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 2845043 — intervention group
Group type: EXPERIMENTAL
Intervention: DMSA 350 mg/m2/day
Number of subjects: 21
Study 2845043 — intervention group
Group type: EXPERIMENTAL
Intervention: DMSA 700 mg/m2/day
Number of subjects: 21
Study 2845043 — intervention group
Group type: EXPERIMENTAL
Intervention: DMSA 1050 mg/m2/day
Number of subjects: 21
Study 2845043 — intervention group
Group type: COMPARATOR
Intervention: CaNa2EDTA 1000 mg/m2/day
Number of subjects: 21
Study 31415213 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional injection of vitamin D3 (0.3 ml, 100,000 IU (2.5 mg/ml))
Number of subjects: 40
Study 31415213 — intervention group
Group type: COMPARATOR
Intervention: Intralesional injection of 2% zinc sulfate
Number of subjects: 40
Study 31823141 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX-hold group (4-week discontinuation)
Number of subjects: 0
Study 31823141 — intervention group
Group type: COMPARATOR
Intervention: MTX-continue group
Number of subjects: 0
Study 31823141 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-week MTX-hold group
Number of subjects: 0
Study 31823141 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week MTX-hold group
Number of subjects: 0
Study 30185421 — intervention group
Group type: EXPERIMENTAL
Intervention: Combinatorial proteomic biomarker assay (CPBA), Videssa Breast
Number of subjects: 663
Study 28332904 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Number of subjects: 86
Study 28332904 — intervention group
Group type: COMPARATOR
Intervention: Surgical turbinoplasty
Number of subjects: 86
Study 24924232 — intervention group
Group type: EXPERIMENTAL
Intervention: Tr14
Number of subjects: 80
Study 24924232 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 23579764 — intervention group
Group type: EXPERIMENTAL
Intervention: exEMS
Number of subjects: 60
Study 23579764 — intervention group
Group type: EXPERIMENTAL
Intervention: limEMS
Number of subjects: 60
Study 23579764 — intervention group
Group type: COMPARATOR
Intervention: CG
Number of subjects: 60
Study 21433074 — intervention group
Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg
Number of subjects: 11
Study 21433074 — intervention group
Group type: COMPARATOR
Intervention: d‐chlorpheniramine 2 mg
Number of subjects: 11
Study 19767812 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine ingestion (5 mg/kg fat-free mass; approximately 208-270 mg)
Number of subjects: 20
Study 17530941 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (3.5 mg.kg(‐1) once weekly for 6 weeks)
Number of subjects: 16
Study 17530941 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline injections once weekly for 6 weeks)
Number of subjects: 16
Study 16123572 — intervention group
Group type: EXPERIMENTAL
Intervention: Totally extraperitoneal preperitoneal hernia repair (TEP)
Number of subjects: 26
Study 16123572 — intervention group
Group type: EXPERIMENTAL
Intervention: Lichtenstein hernia repair (LHR)
Number of subjects: 26
Study 11949239 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression bandaging
Number of subjects: 84
Study 11949239 — intervention group
Group type: COMPARATOR
Intervention: Cryo-pad technology
Number of subjects: 84
Study 10673907 — intervention group
Group type: COMPARATOR
Intervention: 0 micrograms Se/d (as selenomethionine)
Number of subjects: 44
Study 10673907 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 micrograms Se/d (as selenomethionine)
Number of subjects: 44
Study 10673907 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 micrograms Se/d (as selenomethionine)
Number of subjects: 44
Study 10673907 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 micrograms Se/d (as selenomethionine)
Number of subjects: 44
Study 10673907 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 micrograms Se/d (as selenomethionine)
Number of subjects: 44